Werewolf Therapeutics, Inc.

HOWL

US95075A1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 02/07/2024 am IST			5-day change	1st Jan Change
2.35 ^USD	-3.69%		-9.96%	-39.12%

25/06	Werewolf Therapeutics Says Initial Data Show Potential Non-Hodgkin Lymphoma Treatment Increased Therapeutic Window in Phase 1 Clinical Trial	MT
25/06	Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma	CI

WEREWOLF THERAPEUTICS, INC. : Other Events (form 8-K)

January 11, 2023 at 03:03 am IST

Item 8.01. Other Events

As of January 10, 2023, there were 34,275,321 shares of common stock of Werewolf Therapeutics, Inc., a Delaware corporation, issued and outstanding.

--------------------------------------------------------------------------------

Latest news about Werewolf Therapeutics, Inc.

Werewolf Therapeutics Says Initial Data Show Potential Non-Hodgkin Lymphoma Treatment Increased Therapeutic Window in Phase 1 Clinical Trial	25/06	MT
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma	25/06	CI
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1B Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors	01/06	CI
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting	24/05	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	23/04	CI
Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	06/04	CI
JMP Securities Starts Werewolf Therapeutics With Market Outperform Rating, $12 Price Target	03/04	MT
Werewolf Therapeutics' Q4 Net Loss Narrows	08/03	MT
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03	CI
Werewolf Therapeutics, Inc. Appoints Michael Atkins to its Board of Directors	05/01	CI
North American Morning Briefing : Stocks Seen -2-	15/11	DJ
Werewolf Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	04/11	MT
Sector Update: Health Care	04/11	MT
Top Midday Gainers	03/11	MT
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer?s 38th Annual Meeting	03/11	CI
Werewolf Therapeutics, Inc. to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's 38th Annual Meeting	31/23/31	CI
Top Premarket Decliners	25/23/25	MT
Wedbush Starts Werewolf Therapeutics at Outperform With $9 Price Target	24/23/24	MT
Werewolf Therapeutics, Inc. Announces the Investigational New Drug Application Clearance of JZP898 (Formerly Wtx-613), an Engineered IFN Indukine Molecule	10/23/10	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI

Chart Werewolf Therapeutics, Inc.

Duration

Period

More charts

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the bodyâs immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Werewolf Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.44 USD

Average target price

12.5 USD

Spread / Average Target

+412.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
WEREWOLF THERAPEUTICS, INC.	-39.12%	106M
MODERNA, INC.	+16.59%	45.51B
IQVIA HOLDINGS INC.	-9.89%	38.52B
LONZA GROUP AG	+38.08%	38.13B
ALNYLAM PHARMACEUTICALS, INC.	+27.12%	30.74B
CELLTRION, INC.	-8.64%	26.03B
ICON PUBLIC LIMITED COMPANY	+11.81%	25.92B
UNITED THERAPEUTICS CORPORATION	+45.08%	14.13B
MEDPACE HOLDINGS, INC.	+32.85%	12.73B
BIO-TECHNE CORPORATION	-7.19%	11.29B

Other Biotechnology & Medical Research